A comprehensive view of Pfizer Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Fitch: Covid-19 vaccine sales saw strong start to 2022, with Pfizer and Moderna posting stronger-than-expected Q1 sales; 2022 sales could be comparable to significant 2021 numbers, but estimates for 2023 should see more pronounced decrease in market size

Analysts on Enanta suing Pfizer over Covid pill Paxlovid: SVB Securities says it's unclear whether Enanta is in the right, noting patent dates might not prove who 'invented' technology first; RBC says it could take years for lawsuit to reach conclusion

Enanta files suit in US District Court against Pfizer seeking damages for copyright infringement related to Paxlovid nirmatrelvir, ritonavir tablets; Enanta applied for a patent for a coronavirus protease inhibitor in 2020 and received patent this month

Pfizer investing US$25M in biotech firm Akero Therapeutics to fund development of injectable liver drug efruxifermin to treat cirrhotic, cirrhotic non-alcoholic steatohepatitis; deal gives Pfizer 6.7% of Akero’s common stock

Pfizer investing US$95M in vaccine company Valneva SE; investment supports strategic partnership between both companies to develop Lyme disease vaccine

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count